Photo
Corps éditorial
Aitana is an epidemiologist at Epicentre. Her work focuses mainly on the design and implementation of research into vaccination, particularly research aimed at better adapting vaccines to the contexts in which MSF operates.
Carbon emissions of a vaccine trial implemented in Uganda: retrospective assessment to identify actions to enhance researchers' environmental responsibilities.
Journal Reference:
BMJ open 2026 Jul 15; 16(7); . doi: 10.1136/bmjopen-2026-117954. Epub 2026 07 15
Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.
Journal Reference:
Lancet (London, England) 2026 Jan 13; . doi: 10.1016/S0140-6736(25)02069-0. Epub 2026 01 13
Low-Dose Yellow Fever Vaccine in Adults in Africa.
Journal Reference:
The New England journal of medicine 2025 Feb 20; 392(8); . doi: 10.1056/NEJMoa2407293. Epub 2025 02 19
Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines.
Journal Reference:
The Lancet. Infectious diseases 2024 Feb 06; . doi: 10.1016/S1473-3099(24)00008-2. Epub 2024 02 06
The life-long protective immunity of yellow fever vaccination: time to review?
Journal Reference:
The Lancet. Global health 2024 Jan 22; . doi: 10.1016/S2214-109X(23)00594-6. Epub 2024 01 22
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Journal Reference:
The Lancet. Infectious diseases 2023 Apr 28; . doi: 10.1016/S1473-3099(23)00131-7. Epub 2023 04 28
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Journal Reference:
The Lancet. Infectious diseases 2023 Apr 28; . doi: 10.1016/S1473-3099(23)00114-7. Epub 2023 04 28
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
Journal Reference:
Lancet (London, England) 2021 Jan 09; 397(10269); 119-127. doi: 10.1016/S0140-6736(20)32520-4. Epub 2021 01 10
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Journal Reference:
Vaccine 2020 Jun 01; . doi: 10.1016/j.vaccine.2020.04.066. Epub 2020 06 01
Evaluation of the stability of measles vaccine out of the cold chain under extended controlled temperature conditions.
Journal Reference:
Vaccine 2020 Feb 08; . doi: 10.1016/j.vaccine.2020.02.005. Epub 2020 02 08
Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea.
Journal Reference:
Vaccine 2019 Oct 14; . doi: 10.1016/j.vaccine.2019.09.094. Epub 2019 10 14
Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.
Journal Reference:
Vaccine 2018 Sep 25; . doi: 10.1016/j.vaccine.2018.09.009. Epub 2018 09 25
Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda
Journal Reference:
Wellcome Open Research 2019 Nov 21; 4:182;10.12688/wellcomeopenres.15579.1
Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda.
Journal Reference:
BMC infectious diseases 2018 04 11; 18(1); 172. doi: 10.1186/s12879-018-3073-1. Epub 2018 04 11
Vaccination in humanitarian crises: satisficing should no longer suffice.
Journal Reference:
International health 2014 Sep ; 6(3); 160-1. doi: 10.1093/inthealth/ihu051. Epub 2014 08 04
Local discrepancies in measles vaccination opportunities: results of population-based surveys in Sub-Saharan Africa.
Journal Reference:
BMC public health 2014 Feb 21; 14 193. doi: 10.1186/1471-2458-14-193. Epub 2014 02 21
A cluster randomized non-inferiority field trial on the immunogenicity and safety of tetanus toxoid vaccine kept in controlled temperature chain compared to cold chain.
Journal Reference:
Vaccine 2014 Oct 29; 32(47); 6220-6. doi: 10.1016/j.vaccine.2014.09.027. Epub 2014 09 26